MUC16 as a potential target for the surgical detection of pancreatic cancer

摘要

Pancreatic cancer is the third leading cause of cancer-related deaths in the United States. Up to 20% of patients arecandidates for resection, which is currently the only potentially curative treatment option. However, pancreatic cancerpatients have high rates of recurrence after resection due in part to cells left behind at the surgical margin. Fluorescenceguided surgery (FGS) has emerged as a method to improve surgical resection. For pancreatic cancer patients eligible forsurgical resection, intraoperative imaging would serve two purposes. For patients with resectable disease, image-guidancecould help delineate tumor tissue to achieve complete resection. Of critical value, fluorescence guided surgery (FGS) couldbe used to identify locally metastatic disease, which could spare the patient from major, unnecessary surgery and movedirectly to other treatments. Recent studies demonstrated that MUC16 is overexpressed in 60-80% of pancreatic cancers,but this biomarker has not yet been explored for FGS of pancreatic cancer. Herein, we describe the validation anddevelopment of a near infrared fluorescence antibody that recognizes MUC16 for surgical imaging.